Archive: Company News
BellaSeno Announces Publication of First-in-Human Data of its Lead Program Senella
— Successful initial treatment of pectus excavatum patient in Australia
— Data published in the European Journal of Plastic Surgery confirms Bellaseno’s novel approach in soft tissue engineering
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella® in the European Journal of Plastic Surgery. In the trial, a 22-year old patient with severe pectus excavatum received a custom-made, 3D-printed, biodegradable and highly porous Senella® scaffold filled with autologous fat graft to correct her chest deformation.
ImmunOs Therapeutics Appoints Steve Coats, PhD, as Chief Development Officer
– Company adds significant immunotherapy development expertise to its management team
– Clinical trial of lead compound IOS-1002 to start in 2022
ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Steve Coats, PhD, has been appointed as Chief Development Officer.
Mr. Coats brings more than 25 years of industry expertise with a focus on antibody drug development that includes scientific excellence coupled with executive-level success, driving strategic initiatives and innovations in drug development. Read more…
BellaSeno Appoints Tobias Grossner to Chief Medical Officer
— Appointment significantly expands expertise in trauma surgery and clinical development
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the appointment of Dr. med. Tobias Grossner as Chief Medical Officer (CMO).
Dr. Grossner brings strong clinical expertise in trauma surgery and regenerative medicine and has previously been working with BellaSeno as an independent consultant. In addition, Dr. Grossner has been working as a trauma surgery specialist at University Hospital Heidelberg since 2011, most recently as Senior Consultant Trauma Surgery. Read more…
T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that biotech industry veteran Laura Brege has been appointed to the company’s Board of Directors.
“We are excited to welcome Laura to our Board,” stated Thomas M. Soloway, Chief Executive Officer of T-knife. “Laura’s deep experience spans C-suite positions at multiple biotech companies, senior advisory and board roles and tenure as a venture capital investor. Her operational, development and strategic expertise will be valuable as we transition into the clinic early next year with our lead program targeting MAGE-A1-positive solid tumors.”